Targeted Oncology1h
FDA Issues Warning on BioZorb Markers After Recall Due to Patient Complications
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
FDA expands recall of Dynacare baby powder, sent to IL, IN, WI, due to possible asbestos risk
The Food and Drug administration has expanded a recall of Dynacare baby powder, made by the Dynarex Corporation. The recall ...
BioWorld6m
BioFuture 2024: FDA eases the way for cell and gene therapy companies
Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is paving for them, according to a panel of executives who spoke at the BioFuture ...
FDA-approved procedure helps regrow knee cartilage, easing pain
Dr. Rick Lehman performs the MACI procedure, which uses the patient's own cells to regrow cartilage in the knee, eliminating ...
Scripps News on MSN1h
Recall expanded for baby powder that may contain asbestos, FDA says
A recall issued last month for Dynacare brand baby powder over concerns of asbestos contamination has been expanded, the Food ...
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
oncnursingnews2h
October 2024 FDA Approvals for Oncology
October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...
Managed Healthcare Executive1h
FDA Accepts Organon’s Application for Prolia Biosimilar
Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...
Cure Today2h
CAR-T Cell Therapy Receives FDA Designation in Kidney Cancer Subset
Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients ...